MetaVia (NASDAQ:MTVA) Issues Quarterly Earnings Results

MetaVia (NASDAQ:MTVA) announced its earnings results on Thursday. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.08), FiscalAI reports.

MetaVia Trading Up 2.8%

Shares of MetaVia stock traded up $0.04 on Friday, reaching $1.49. 107,022 shares of the company were exchanged, compared to its average volume of 549,292. MetaVia has a fifty-two week low of $0.97 and a fifty-two week high of $19.03. The firm has a market capitalization of $7.69 million, a price-to-earnings ratio of -0.29 and a beta of 0.95. The stock has a fifty day moving average price of $1.72 and a 200-day moving average price of $1.75.

Hedge Funds Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC purchased a new stake in shares of MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia at the end of the most recent quarter. 1.37% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on MTVA shares. Wall Street Zen upgraded shares of MetaVia to a “sell” rating in a research note on Saturday, June 20th. HC Wainwright restated a “buy” rating on shares of MetaVia in a research report on Friday, July 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research note on Tuesday, July 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $20.00.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.